Entering text into the input field will update the search result below

Femasys' FemCerv tissue sampler for cervical cancer diagnosis receives product approval in Canada, stock rises 10%

May 03, 2023 9:14 AM ETFemasys Inc. (FEMY)By: Dania Nadeem, SA News Editor
Dilation and curettage (d and c).endometrial biopsy.cervical cancer.3d illustration

Mohammed Haneefa Nizamudeen/iStock via Getty Images

  • Femasys' (NASDAQ:FEMY) endocervical tissue sampler FemCerv received product approval from Health Canada and the Public Health Agency of Canada.
  • FEMY is up ~10% before the bell.
  • FemCerv is designed to collect and contain a comprehensive sample to maximize quality and quantity.
  • FemCerv captures tissue sample with minimal pain and has the potential to improve the standard of care for diagnosing cervical cancer.
  • FemCerv is designed to be used with colposcopy and capture a comprehensive 360-degree tissue sample in a pain-free office visit, maximizing quality and quantity.
  • Press Release

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.